» Articles » PMID: 22120376

Incidence Trends in the Anatomic Location of Primary Malignant Brain Tumors in the United States: 1992-2006

Overview
Journal World Neurosurg
Publisher Elsevier
Date 2011 Nov 29
PMID 22120376
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background: This study sought to determine incidence trends of the anatomical origin of primary malignant brain tumors.

Methods: Incidence data for histologically confirmed brain tumors were obtained from the Los Angeles County Cancer Surveillance Program (LAC), the California Cancer Registry (CCR), and the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program for 1992 to 2006. Age-adjusted incidence rates (AAIR) and annual percent changes (APC) were calculated by histologic subtypes and anatomic subsites. Statistical analyses were performed using the SEER*Stat analytic software and SAS statistical software.

Results: Increased AAIRs of frontal (APC +2.4% to +3.0%, P ≤ 0.001) and temporal (APC +1.3% to +2.3%, P ≤ 0.027) lobe glioblastoma multiforme (GBM) tumors were observed across all registries, accompanied by decreased AAIRs in overlapping region GBMs (-2.0% to -2.8% APC, P ≤ 0.015). The AAIRs of GBMs in the parietal and occipital lobes remained stable. The AAIR of cerebellar GBMs increased according to CCR (APC +11.9%, P < 0.001). The AAIR of all gliomas, which includes all anatomical subsites, decreased (-0.5% to -0.8% APC, P ≤ 0.034). Low-grade and anaplastic astrocytomas demonstrated decreased AAIRs in the majority of brain regions.

Conclusions: Data from 3 major cancer registries demonstrate increased incidences of GBMs in the frontal lobe, temporal lobe, and cerebellum, despite decreased incidences in other brain regions. Although this may represent an effect of diagnostic bias, the incidence of both large and small tumors increased in these regions. The cause of these observed trends is unknown.

Citing Articles

Advancements in Imaging and Neurosurgical Techniques for Brain Tumor Resection: A Comprehensive Review.

Vadhavekar N, Sabzvari T, Laguardia S, Sheik T, Prakash V, Gupta A Cureus. 2024; 16(10):e72745.

PMID: 39618625 PMC: 11607568. DOI: 10.7759/cureus.72745.


Oncolytic Virotherapy for High-Grade Glioma and Current Evidence and Factors to Consider for Incorporation into Clinical Practice.

Soldozy S, Eichberg D, Morell A, Luther E, Lu V, Higgins D Pathogens. 2023; 12(7).

PMID: 37513708 PMC: 10386040. DOI: 10.3390/pathogens12070861.


Association between preoperative neurocognitive status and IDH1 mutation status in high-grade gliomas.

Liouta E, Kalyvas A, Komaitis S, Drosos E, Koutsarnakis C, Garcia-Gomez J Neurooncol Pract. 2023; 10(2):132-139.

PMID: 36970174 PMC: 10037936. DOI: 10.1093/nop/npac077.


Scientific evidence invalidates health assumptions underlying the FCC and ICNIRP exposure limit determinations for radiofrequency radiation: implications for 5G.

Environ Health. 2022; 21(1):92.

PMID: 36253855 PMC: 9576312. DOI: 10.1186/s12940-022-00900-9.


The Role of Stereotactic Frame-Based Biopsy for Brainstem Tumors in the Era of Molecular-Based Diagnosis and Treatment Decisions.

Hirano Y, Shinya Y, Aono T, Hasegawa H, Kawashima M, Shin M Curr Oncol. 2022; 29(7):4558-4565.

PMID: 35877220 PMC: 9318548. DOI: 10.3390/curroncol29070360.